-
公开(公告)号：WO2021232062A1
公开(公告)日：2021-11-18
申请号：PCT/US2021/070551
申请日：2021-05-13
申请人： FIGENE, LLC
发明人： O'HEERON, Pete , ICHIM, Thomas
IPC分类号： A61K35/30 , A61P25/16 , C12N5/07 , C12N5/079 , C12N5/0793
摘要： In some aspects, disclosed herein are methods and compositions for treatment of Parkinson's disease using fibroblasts or cells derived from fibroblasts. Also disclosed herein are methods and compositions for generating dopaminergic cells from fibroblasts. Dopaminergic cells generated from fibroblasts are described. Methods of the present disclosure include methods for treatment or preventing of Parkinson's disease comprising the use of fibroblasts or dopaminergic cells generated from fibroblasts.
-
2.发明申请
公开(公告)号：WO2021226627A1
公开(公告)日：2021-11-11
申请号：PCT/US2021/070504
申请日：2021-05-04
申请人： FIGENE, LLC
发明人： O'HEERON, Pete , ICHIM, Thomas
摘要： Disclosed are treatments, compositions of matter, and protocols for reducing, ameliorating, or reversing excess inflammation and/or cytokine storm through administration of Sphagnum and/or extracts thereof. In particular embodiments, a patient at risk for cytokine storm is administered a Sphagnum extract at a concentration sufficient to induce an immunomodulatory change in said patient, including suppression of macrophage activation, reduction of neutrophil activation and inhibition of DNA extracellular trap release. In some embodiments, Sphagnum, or extracts thereof are administered together with other agents to enhance activity in treatment of Covid-19 infection and associated pathologies. In some embodiments, humic acid and/or analogues thereof are administered for reduction of pathological inflammation and/or stimulation of immunity.
-
公开(公告)号：WO2021222943A1
公开(公告)日：2021-11-04
申请号：PCT/US2021/070496
申请日：2021-04-30
申请人： FIGENE, LLC
发明人： ICHIM, Thomas
摘要： Aspects of the present disclosure are directed to methods and compositions for inducing the generation of cells capable of killing cancer associated fibroblasts at least in part through the generation of ex vivo expanded cord blood cells which are programmed to kill cancer associated fibroblasts. Certain aspects relate to generation of immune cells, including T cell and Natural Killer (NK) cells, for use in targeting cancer cells and cancer associated fibroblasts. Further aspects are directed to gene editing and/or gene silencing of immune checkpoint proteins in therapeutic immune cells.
-
公开(公告)号：WO2021216365A1
公开(公告)日：2021-10-28
申请号：PCT/US2021/027654
申请日：2021-04-16
申请人： FIGENE, LLC
发明人： ICHIM, Thomas
摘要： Disclosed are means of enhancing therapeutic effects of fibroblast administration through utilization of extracorporeal shock waves. In one embodiment, enhancement of intravenously administered fibroblast therapeutic activity is accomplished by introducing extracorporeal shock waves to the patient in need of therapy. In one specific embodiment, enhancement of the ability of fibroblasts administered intravenously to treat a condition is accomplished by exposure of areas areas affected by the condition to extracorporeal shock waves. In another specific embodiment, the invention provides transfection of IL-12 and/or IL-23 into fibroblasts to augment regenerative activity, including neuroregenerative and anticancer activity. In further embodiments the invention provides augmentation of regenerative activity by induction of T regulatory cells utilizing IL-35 transfection, wherein said T regulatory cells provide an optimized environment for stimulation of regenerative activity.
-
公开(公告)号：WO2021133798A1
公开(公告)日：2021-07-01
申请号：PCT/US2020/066602
申请日：2020-12-22
申请人： FIGENE, LLC
发明人： O'HEERON, Pete , ICHIM, Thomas
IPC分类号： A61K35/33 , C07K14/525 , A61P29/00 , A61P37/00
摘要： Disclosed are means of suppressing production of the inflammatory cytokine TNF-alpha through contact-dependent and contact-independent means by fibroblast populations and products and/or derivatives of fibroblast populations. In one embodiment, fibroblasts are cultured under conditions allowing proliferation of said fibroblasts, wherein said proliferative status of fibroblasts correlates with the ability to directly suppress TNF-alpha production, and/or to release one or more factors capable of suppressing TNF-alpha production. In one embodiment, fibroblasts are used for treatment of inflammatory diseases by their ability to suppress TNF-alpha production. In other embodiments, conditioned media and/or exosomes of said fibroblasts are utilized to treat inflammatory diseases by their ability to suppress TNF-alpha production.
-
6.发明申请
公开(公告)号：WO2021133793A1
公开(公告)日：2021-07-01
申请号：PCT/US2020/066591
申请日：2020-12-22
申请人： FIGENE, LLC
发明人： ICHIM, Thomas , O'HEERON, Pete
摘要： Embodiments of the disclosure concern reducing deleterious effects of inflammatory cytokines, such as interleukin-17, by providing to an individual with inflammation or at risk for inflammation an effective amount of fibroblasts and/or fibroblast derivatives thereof that reduce production of IL-17 from immune cells, that suppress responsiveness of cells to IL17, and/or that suppress generation of Th17 cells.
-
公开(公告)号：WO2021243380A1
公开(公告)日：2021-12-02
申请号：PCT/US2021/070642
申请日：2021-05-29
申请人： FIGENE, LLC
发明人： ICHIM, Thomas
IPC分类号： A61K9/00 , A61K35/74 , A61K35/741 , A61K35/742 , A61K35/745 , A61K35/747
摘要： Disclosed are means, methods, and compositions of matter useful for enhancing therapeutic efficacy of fibroblasts, fibroblast products such as exosomes, or fibroblast apoptotic bodies, through modulation of the recipient microbiome prior to, concurrent with, and subsequent to administration of fibroblasts. In one embodiment, assessment of dysbiosis is performed prior to administration of fibroblast therapy, and dysbiosis is repaired by means including: a) microbiome transplant; b) prebiotic treatment; and/or c) probiotic treatment.
-
公开(公告)号：WO2021232064A2
公开(公告)日：2021-11-18
申请号：PCT/US2021/070555
申请日：2021-05-14
申请人： FIGENE, LLC
发明人： ICHIM, Thomas
摘要： Disclosed herein are methods and compositions for treating or preventing ovarian failure using fibroblasts or cells derived from fibroblasts. In some embodiments, ovarian failure is pathological, the result of an intervention, or the result of aging. In some embodiments, regenerative fibroblast cells are administered locally into the ovary or peri-ovary areas or systemically. In some embodiments, regenerative cells act to suppress fibrosis of the ovaries, inhibit inflammation, stimulate maturation of immature ovarian progenitor cells, or directly differentiate into oocytes. In some embodiments, regenerative fibroblasts produce factors that inhibit apoptosis of oocytes and/or oocyte progenitors.
-
公开(公告)号：WO2021211386A1
公开(公告)日：2021-10-21
申请号：PCT/US2021/026752
申请日：2021-04-10
申请人： FIGENE, LLC
发明人： ICHIM, Thomas
摘要： In some aspects, disclosed herein are methods and compositions for treatment of erectile dysfunction using regenerative fibroblasts or cells derived from fibroblasts. Methods and compositions disclosed also include those for generating regenerative fibroblast cells from fibroblasts. Also disclosed are methods and compositions for treatment of erectile dysfunction using regenerative fibroblast-conditioned media. Regenerative fibroblast cells generated from fibroblasts and regenerative fibroblast-conditioned media are also described.
-
公开(公告)号：WO2021207192A1
公开(公告)日：2021-10-14
申请号：PCT/US2021/025959
申请日：2021-04-06
申请人： FIGENE, LLC
发明人： ICHIM, Thomas
摘要： Disclosed herein are methods and compositions for reducing inflammation in a subject. Aspects are directed to reduction of pulmonary inflammation using fibroblasts or fibroblastderived products. In some cases, fibroblasts or fibroblast-derived products are provided to a subject to reduce pulmonary inflammation, thereby treating or preventing airway allergy, asthma, or asthma-related symptoms. Embodiments encompass use of fibroblast-derived products, including exosomes, conditioned media, and other components derived from fibroblasts.
-
-
-
-
-
-
-
-
-
搜索结果
58 条记录 (耗时 0.021 秒)
